#healthsystems >> 📊 Progress of Poland in developing its cancer care system 🏥 Cancer is the second leading cause of death in Poland. Although the incidence of cancer is low in comparison to other European countries, mortality and survival ratios are worse than Europe’s average.83 Overall cancer mortality was 15% higher than the EU average of 247 / 100,000 in 2019, despite incidence rates that were 5% and 3% lower than the EU for men and women respectively. Poland’s health system is based on universal social health insurance that covers almost all residents. Recent reforms have focused on improving organization of care for key health problems such as cancer. Presently, the country fully reimburses over 60% of novel oncology therapies, and the National Health Fund supports the use of more than 100 authorized novel agents. 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗺𝗮𝗱𝗲 𝗶𝗻 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗮𝗻𝗱 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 🩺 There are screening programs for breast, cervical, and colorectal cancers, but the participation of target groups is low, at 16%, 20%, and 40% respectively.87 Poland was the second country in Europe to implement a nationwide screening program for lung cancer, doing so in 2020. A population-based cervical screening program was implemented in 2006, and has led to a decrease in deaths from cervical cancer; however, screening rates are low in comparison to other European countries, and the screening procedure is carried out in gynecologist’s offices rather than in primary care. 𝗦𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗹𝗲 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 💰 Poland has recognized the need to improve the organization of cancer care in areas such as reducing waiting lists for both diagnostics and treatments. On Jan 1st, 2015 the country implemented a controversial oncological therapy fast-track known as the oncological package, which led to significantly shortened diagnostic and treatment times. The oncological package also aimed to abolish financing limits on the coverage of services provided in the pathway, a move that led to a substantial increase in spending, from €1.6bn in 2014 to €2.2bn in 2019. 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 📱 E-health has been recognized as playing a pivotal role in meeting health priorities. Poland has initiated an eHealth Development Programme, focusing on enhancing primary care with e-health solutions as part of the goals of the national strategy, known as the Healthy Future Strategy framework. The strategy outlines the goals that Poland is utilizing to progress its medical infrastructure, and it establishes new benchmarks, goals, and preferences for the financial, societal, health, and geographical growth of its population. 𝗙𝘂𝗹𝗹 𝗿𝗲𝗽𝗼𝗿𝘁: https://lnkd.in/dqfKs7xJ #healthcare #cancercare #oncology #poland #easterneurope
Eirhub’s Post
More Relevant Posts
-
Understanding the costs and benefits of investing in cancer Posted by: Brian Ferguson, Posted on: 1 November 2016 - Understanding the costs associated with cancer is vital in order that resources are used for maximum effect. And investing in prevention and early intervention is critical if we are going to reduce the emotional and physical impact of cancer on individuals, families, friends and those that care for people with cancer. Calculating the health care and wider costs of cancer - as well as assessing the cost-effectiveness of prevention, early intervention and treatment - is a fundamental challenge faced by decision makers across the health and social care system. The costs of cancer can be felt at an individual level: work by Macmillan has shown that most (83%) cancer patients incur an average cost of £570 per month as a result of their illness. It can also be felt in the national economy: Oxford University estimate the cost of cancer to the economy is £7.6 billion a year due to premature deaths and time taken off work. Costs and the health system The Independent Cancer Taskforce Report (ICTR) set out the need for there to be clearer accountability of spend on cancer and emphasised the need for action in prevention and early diagnosis to reduce the longer term burden on the health system. It says: “The National Audit Office has estimated cancer services cost the NHS approximately £6.7bn per annum in 2012/13. The Five Year Forward View projections indicate that this will grow by about 9% a year, implying a total of £13bn by 2020/21.” Recommendation 95 in the strategy specifically asks that: “NHS England and Public Health England should work with Monitor and other bodies to consider how to develop better health economic evaluation of new service models and interventions.” We have a dedicated health economics team that commissions work to assess the economic impact of prevention and early intervention, and an example of this is recent work on bowel cancer in direct response to Taskforce Recommendation 95. This work has summarised the available cost-effectiveness evidence. Cost-effectiveness is a key concept in health economics and is concerned with the value we get from the money spent – where value is often expressed in terms of improving both survival and quality of life. For instance if we invested resources in the best possible way in bowel cancer then we would see improvements in survival, and also improvements in the quality of life of individuals who are staged earlier and therefore do not suffer the more unpleasant effects of treatment that could potentially be avoided. This is why a ‘return on investment’ (RoI) type approach has been followed in this work: how do we make sure that resources are invested in such a way that we achieve health gains at the same time as avoiding health care and other system costs further down the line.
To view or add a comment, sign in
-
Understanding the costs associated with cancer is vital in order that resources are used for maximum effect. And investing in prevention and early intervention is critical if we are going to reduce the emotional and physical impact of cancer on individuals, families, friends and those that care for people with cancer. Calculating the health care and wider costs of cancer - as well as assessing the cost-effectiveness of prevention, early intervention and treatment - is a fundamental challenge faced by decision makers across the health and social care system. The costs of cancer can be felt at an individual level: work by Macmillan has shown that most (83%) cancer patients incur an average cost of £570 per month as a result of their illness. It can also be felt in the national economy: Oxford University estimate the cost of cancer to the economy is £7.6 billion a year due to premature deaths and time taken off work. Costs and the health system The Independent Cancer Taskforce Report (ICTR) set out the need for there to be clearer accountability of spend on cancer and emphasised the need for action in prevention and early diagnosis to reduce the longer term burden on the health system. It says: “The National Audit Office has estimated cancer services cost the NHS approximately £6.7bn per annum in 2012/13. The Five Year Forward View projections indicate that this will grow by about 9% a year, implying a total of £13bn by 2020/21.” Recommendation 95 in the strategy specifically asks that: “NHS England and Public Health England should work with Monitor and other bodies to consider how to develop better health economic evaluation of new service models and interventions.” We have a dedicated health economics team that commissions work to assess the economic impact of prevention and early intervention, and an example of this is recent work on bowel cancer in direct response to Taskforce Recommendation 95. This work has summarised the available cost-effectiveness evidence. Cost-effectiveness is a key concept in health economics and is concerned with the value we get from the money spent – where value is often expressed in terms of improving both survival and quality of life. For instance if we invested resources in the best possible way in bowel cancer then we would see improvements in survival, and also improvements in the quality of life of individuals who are staged earlier and therefore do not suffer the more unpleasant effects of treatment that could potentially be avoided. This is why a ‘return on investment’ (RoI) type approach has been followed in this work: how do we make sure that resources are invested in such a way that we achieve health gains at the same time as avoiding health care and other system costs further down the line.
To view or add a comment, sign in
-
Leading – from which end? Screening and innovative treatment options required! Two articles made me think of the effects of healthcare systems on patient outcomes. The economist identifies obstacles in early diagnoses of cancer. The NHS lacks behind in capacity and referral times. On top, corona lockdowns delayed screening and routine visits. This decreased the one-year survival rate of patients diagnosed with colorectal cancer from 79 to 76%. The guardian addresses the U-turn of the NHS. The NHS makes two innovative cancer drugs available. How often did the NICE / NHS not perform a U-turn? What is the result of the health benefit assessment procedures? In which way do they affect the treatment outcomes of patients? So, what’s the message for the LifeSciences industry? One: be creative! Develop technologies, platforms and business models to put in place screening approaches. The European Beating Cancer Plan is a brilliant framework for this – within the EU though. The delay of diagnoses based on lockdown decreases the survival rate. The early detection of cancer should turn around this logic. Two: Work with the obstacles of the assessment processes in place. Find the spot in the healthcare ecosystem where your organization can deliver best for the patient outcome. This also implies working on different levels in the ecosystem together. Align your strategy and action across functions. Otherwise, they lack orientation and power. Economist article:
To view or add a comment, sign in
-
Cancer Doctor | Scientist | Pilot | LinkedIn Top Voice | Force Multiplier Educator | Speaker | Travel Blogger | Girl Dad & Husband (Disclosure: All posts are my personal opinion, and unrelated to my employer)
I was humbled to be featured on Doximity to discuss key findings from the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. I focus on important issues and concepts relating to Health Care Access and Equity in prostate cancer. Prostate cancer is the most common cancer in men in the U.S. There are differences, based on rural or metropolitan/urban geography, in patient demographics, clinical presentation, treatment patterns, and cancer-related outcomes. 📍 KEY TAKEAWAYS 📍 📈 This was a study of prostate cancer patients in Georgia and their cancer-specific outcomes, matched between provider location and patient geography in Rural vs. Metropolitan areas. 📈 RURALITY was defined as areas with fewer than 20,000 people who were not adjacent to metropolitan areas. 📈 Retrospective analysis of > 75,000 patients in SEER database with a median age of 72 years, with >95% of patients participating from metropolitan areas. 📈 All-cause mortality was found to be 44% higher, and cardiac mortality 33% higher, in patients from Rural Areas with non-metropolitan providers. 📈 Nevertheless, the target population they wished to study (despite their best efforts and optimization) was highly under-represented in this analysis. 📍 FUTURE STEPS 📍 🙌 Recognize the importance of RURALITY and its impact on outcomes. 🙌 Define and systematically investigate RURALITY in all types of cancers. 🙌 Sub-analyses of possible factors and variables in this population: Underlying baseline health or co-morbidities, ethnicity, belief system, diet and BMI, family history of cancer, income status and also type of employment, proximity of the community to potential toxic environmental exposures, insurance status, stage of diagnosis including disease detected early as compared to advanced or metastatic stages, and length of time from diagnosis to referral to effective treatment rendered. 📍 QUESTIONS FOR GROUP DISCUSSION 📍 Rural residence status has a major impact on cancer care, and is a key socioeconomic determinant of outcomes. 1) How can we increase equitable access to quality, time-sensitive, compassionate care for cancer? 2) How can we best design interventions to mitigate rural-urban disparities? 3) How do we increase enrollment of this vulnerable population into clinical trials? Watch the full video here: https://lnkd.in/gvK6NVzR If you liked this post, ♻ FEEL FREE TO REPOST ♻ and also connect with me. 🔺 Follow and Connect with HardeepMD: https://lnkd.in/gsuPq5Ac 🔺 Join the Cancer Journeys Group: https://lnkd.in/gDWshDrr 🔺 Join the Sports Transformation Journey Group: https://lnkd.in/gnhnr8Yb 🔺 Enjoy the Instagram Video Reels Page: https://lnkd.in/gqXBeZmw #prostatecancer #asco #clinicaltrials #oncologyresearch #ascogu #ascogu24 #rurality #metropolitan #urbanhealth #equity #accesstocare #healthcare #healthcareequity #outcomes #empathy #cancercare
To view or add a comment, sign in
-
According to projections by the World Health Organisation (WHO), an estimated 35 million new cases of cancer will emerge by the year 2050. Recent reports from the International Agency for Research on Cancer highlight lung, breast, prostate and colorectal cancers as the most prevalent types globally. Significant disparities in cancer mortality exist across different regions, particularly between countries with very high human development indexes and those with low indexes. In nations with low human development indexes, there were approximately 811,014 new cancer cases and 543,337 deaths, while in countries with very high human development indexes, there were 9,296,171 new cases but only 3,643,502 deaths. A WHO report released on February 4 documented a notable increase in global cancer incidence. Similarly, a study published in the British Medical Journal, https://lnkd.in/dQTKN2fK in September 2023 reported a significant rise in cancer cases among individuals under 50 years old. Although completely eradicating cancer remains a contentious challenge, there are opportunities for prevention and wider types of treatments. Governments and medical organisations, such as AMN, can play pivotal roles in raising awareness and enhancing understanding of cancer risk. Enhancing educational programs to facilitate collaboration among multidisciplinary medical and health professionals represents a proactive and beneficial initiative aimed at better equipping clinicians through training. At the individual level, people can take proactive measures to reduce personal risk factors. For instance, quitting smoking can lower the risk of several cancer types. Adopting a healthy diet, maintaining a suitable weight, managing stress effectively, ensuring sufficient sleep, staying physically active, and limiting alcohol consumption are additional steps individuals can take to mitigate their risk of cancer.
To view or add a comment, sign in
-
-
Globally, cervical cancer ranks as the fourth most common cancer among women, presenting a significant health crisis, particularly in low and middle-income countries (LMIs). In these regions, the challenge of accessing and affording preventive healthcare screenings for cervical cancer is a formidable barrier. Early detection is crucial, as it transforms cervical cancer from a fatal disease into a preventable and curable condition. Yet, the absence of effective screening programs in LMIs leads to it being a major cause of female mortality. The hurdles to overcoming this issue are not merely medical but are deeply rooted in logistical and socioeconomic factors, creating significant health disparities and underscoring the critical need for innovative healthcare solutions. To bridge this gap, Pragmatech Healthcare Solutions Pvt. Ltd. has introduced CERVICHECK™, aiming to revolutionize the approach to cervical cancer screening by making it more accessible and affordable. This initiative is distinct from traditional screening methods, which often depend on the existing healthcare infrastructure and require individuals to seek out services. Instead, CERVICHECK by Pragmatech Healthcare Solutions Pvt. Ltd.™ proactively extends these life-saving screenings to women, directly addressing and surmounting the logistical and economic obstacles that have traditionally impeded access to preventive care. Behind this transformative project is a team of visionary founders - Anirban Palit, Palna Patel, Sayantani Pramanik Palit, Ph.D., and 𝗗𝗿. 𝗕𝗵𝗮𝗴𝗶𝗿𝗮𝘁𝗵 𝗠𝗼𝗱𝗶 whose deep market insight and unwavering dedication to making a tangible difference have positioned their enterprise as a pioneer in healthcare innovation. Their endeavor is not just about introducing a product but about igniting a movement towards achieving health equity and democratizing preventive screening across India and other LMIs. CERVICHECK™, as the flagship product of Pragmatech Healthcare Solutions, encapsulates the company's strategic approach to healthcare: making screening services not only more accessible but also reliable and cost-effective. 𝗕𝘆 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝘇𝗶𝗻𝗴 𝗲𝗮𝗿𝗹𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗶𝗻𝘁𝗲𝗿𝘃𝗲𝗻𝘁𝗶𝗼𝗻, this approach not only aims to significantly decrease the incidence of cervical cancer but also establishes a new benchmark for preventive healthcare in settings constrained by resources. Through its commitment to improving health outcomes, the project exemplifies the impactful role that targeted healthcare innovations can play in addressing and ameliorating global health challenges. Learn More Website:https://pragmatech.co.in/
To view or add a comment, sign in
-
-
The Center for Global Health Equity was established in 2023, but the legwork behind its many partnerships, programs, and initiatives began long ago – most likely with a conversation. Recently, Timothy Rebbeck, PhD, Dana-Farber researcher and director of the Center for Global Health Equity, initiated three new and ongoing conversations with health leaders from South Sudan, Uzbekistan, and the United Kingdom. The discussions explored the potential for building new partnerships that will help improve cancer research, education, and care worldwide. “Every interaction is different,” says Rebbeck. “But in all cases our first goal is to build trust so that we can form relationships that are sustainable and jointly beneficial.” The Republic of South Sudan is in sub-Saharan Africa to the west of Ethiopia. The country has limited cancer prevention and care facilities. Their Minister of Health, Yolanda Awel Deng Juach, MD, and Undersecretary for Health, Ader Macar Aciek, MD, and others met with Rebbeck at Dana-Farber in February to discuss the country’s efforts to develop a National Cancer Control Plan. The group explored opportunities for collaboration and discussed the potential for Dana-Farber experts to advise South Sudan’s health leaders on the creation of a plan. “The discussion is in early stages,” says Rebbeck. “We won’t have a ground presence in South Sudan, but we hope to provide advice as they develop their capacity to provide cancer care.” The country of Uzbekistan is located in Central Asia. In the capital city of Tashkent, the Ministry of Health is building an 800-bed cancer hospital that is intended to be a regional referral center for cancer, not just for Uzbekistan but throughout Central Asia. Rebbeck traveled to Uzbekistan and subsequently, he and David Read, MBA, MPH, vice president of Ambulatory Care Operations, met with Jasur Saydaxmedov and Kozimkhon Khujaev of the Uzbek Embassy, and Furkat Sidikov, the Uzbek Ambassador to the US and others to discuss opportunities for collaboration with Dana-Farber. He also met with the Ambassador from Uzbekistan here in Boston. Uzbekistan’s health leaders are looking for expertise on the training of medical students and physicians, as well as educating the public about cancer. They also are interested in guidance on research that can improve cancer care there and in best clinical care practices. “We are actively engaged in conversations about how Dana-Farber can assist the Government of Uzbekistan to build the cancer capacity they envision,” says Rebbeck. Rebbeck also met with the British Consul General to New England, Peter Abbott, PhD, OBE, to talk about ways the US and the UK can work together to advance global cancer health. ⬇ Timothy Rebbeck with the Minister of Health (middle) and the Undersecretary to the Minister of Health (right) of South Sudan at Dana-Farber. More: https://lnkd.in/eiVWTfcr
To view or add a comment, sign in
-
-
Survivorship and Supportive Care Leader | Patient Advocate | Nonprofit Board Volunteer | Lifestyle Medicine
Thoughts on Day 2 of Biological Effectors of Social Determinants of Health in Cancer: Identification and Mitigation: A Workshop When: Day 2 | Workshop: Thursday, March 21, 2024, 8:30 a.m. - 11:30 a.m. ET The core of the conference focused on how to solve SDOH through data solutions along with research focused on building specific interventions. However a key driver in the poor outcomes is the lack of supportive care infrastructure. Rob Winn's commented that he is worried about the current cancer drugs shortages and how they will disproportionally impact certain populations. I agree that when there is a lack of resources they will go to those who know how to advocate for them. Health care leaders should also realize that when there is a lack of comprehensive proactive supportive care that the individuals that will suffer the most are those that are dependent on the system to address their complicated SDOH needs. It's a miss that providers focused on survivorship and supportive care like myself are generally not included in these conferences. Creation of well planned and comprehensive supportive care links the patient to the specific resources that are needed through a system that is not random but designed to make sure every individual is risk stratified to the level of care based on their needs. In addition care is not just focused in the brick and mortar cancer center but follows survivors to their communities through lay navigators, CHW, health coaches and community organizations with bidirectional communication between oncology and community teams. The need for these well planned systems were demonstrated well by the representative quotes in Nicole Stout DPT, CLT-LANA, FAPTA recent journal article "Unmet Needs and Care Delivery Gaps Among Rural Cancer Survivors." https://lnkd.in/gBrnBmz2 Here are some examples of system failures: Throughout the whole thing, I only ever got what I needed because I followed up, not because they followed up, but because I pushed…that I was the one that made calls and contacts to find help. We asked about the financial assistance program, but they said we don’t qualify because my husband works, they said to talk to a social worker, but I don’t have one and we really didn’t have anyone to help figure it out I'll tell you what nutritional counseling would've helped me a great deal. I was losing weight and losing weight and they kept saying eat…I needed some coaching on eating, I just wasn’t hungry. The dietician at the hospital was so helpful but she was the only one and I would only see her when I was in for treatments…no one close to home for me.
Unmet Needs and Care Delivery Gaps Among Rural Cancer Survivors
ncbi.nlm.nih.gov
To view or add a comment, sign in
-
𝐓𝐡𝐞 𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐆𝐥𝐨𝐛𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐫𝐢𝐬𝐢𝐬: 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐚𝐧𝐝 𝐂𝐚𝐥𝐥𝐬 𝐟𝐨𝐫 𝐀𝐜𝐭𝐢𝐨𝐧 Cancer remains a formidable adversary in global health, ranking as the second leading cause of mortality worldwide. This devastating disease affects not only humans but also our beloved pets, as evidenced by the personal experience of many, including those watching their dogs succumb to cancer. While cardiovascular diseases are on the decline, cancer rates continue to rise, presenting a complex challenge for healthcare systems and researchers alike. The sheer volume of cancer data across various demographics and cancer types is staggering, making it a multifaceted issue to address. Recently, Dr. Monique Gary, a board-certified breast surgical oncologist, shared insights with CancerNetwork® about the projected increases in global cancer burden and the potential exacerbation of cancer inequities among underserved populations. A World Health Organization (WHO) survey paints a grim picture of the future cancer landscape. In 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths. The survey projects that by 2050, new cancer cases could surge to over 35 million annually, representing a staggering 77% increase from 2022 figures. Perhaps most alarming is the prediction that one in five people will develop cancer in their lifetime, with mortality rates estimated at one in nine men and one in twelve women. Dr. Gary highlighted a particularly concerning trend: the rise in cancer diagnoses among younger patients, including those without family history or known genetic predispositions. This shift challenges the traditional understanding of cancer risk factors and emphasizes the need for a more comprehensive approach to cancer prevention and early detection. ◽ Global cancer burden is projected to increase significantly, with an estimated 35 million new cases by 2050 (77% increase from 2022). ◽ Cancer diagnoses are rising among younger patients, even those without a family history. ◽ Environmental factors and health conditions contribute to the rising burden. ◽ Healthcare inequities worsen cancer outcomes for underserved populations. ◽ Clinicians need to be more aware of cancer risk in younger patients. ◽ Oncologists should encourage patient participation in clinical trials. From primary care to specialised oncology, from research institutions to policy-making bodies, everyone has a part to play in turning the tide against cancer and ensuring equitable access to prevention, early detection, and treatment for all. All medical professionals have a role to play in reducing cancer disparities. Source: Cancer Network #AdipoLABs #Hyperthermia #Education #Innovation #MedicalDevice #Remission1C #Healthcare #Cancer
To view or add a comment, sign in
-
-
As the World Health Organization (World Health Organization) observes World Cancer Day, the IARC - International Agency for Research on Cancer / World Health Organization (IARC) released estimates indicating a rising global cancer burden. In 2022, an estimated 20 million new #cancercases and 9.7 million #deaths were reported, #underscoring the urgent need to address #cancerinequities. World Health Organization's survey across 115 countries revealed that a majority do not adequately finance priority cancer and palliative care services, emphasizing disparities in universal health coverage (UHC). The IARC's #GlobalCancerObservatory highlighted ten major cancer types, with lung cancer topping the list, followed by breast and colorectal cancers. Lung cancer emerged as the leading cause of cancer-related deaths, underscoring the persistent impact of #tobacco use, particularly in Asia. Cervical cancer was the eighth most #commoncancer globally, affecting 661,044 individuals and causing 348,186 deaths, with a #significant prevalence in sub-Saharan Africa. Cancer disparities based on Human Development Index (HDI Group) were evident, notably in #breastcancer. In very high HDI countries, women face a 1 in 12 chance of being diagnosed with breast cancer in their lifetime, compared to 1 in 27 in low HDI countries. The likelihood of breast cancer mortality is higher in low HDI Group countries, emphasizing the critical importance of timely diagnosis and quality treatment. WHO's survey on health benefit packages (HBPs) revealed substantial global inequities in cancer services. High-income countries exhibited a 4–7 times higher likelihood of including #lungcancer-related services in HBPs compared to lower-income countries. The survey underscored the urgent need for investments to address global cancer outcome disparities. The report also projected a #considerableincrease in the cancer burden, estimating over 35 million new cases in 2050—a 77% increase from 2022. High HDI countries are expected to experience the greatest absolute increase, with an additional 4.8 million new cases predicted in 2050. However, the proportional #increase is most pronounced in low and medium HDI countries, emphasizing the uneven impact of the global cancer burden. Dr. Bente Mikkelsen, Director of the #DepartmentofNoncommunicable Diseases at WHO, highlighted the need for major investments to address global inequities in cancer outcomes and emphasized ongoing efforts to develop, finance, and implement policies promoting #cancercare for all. The report emphasizes the importance of political will to ensure that everyone has access to affordable, quality cancer services, regardless of their geographical location or socioeconomic statu #News #Medlr #Healthnews #Healthcare
WHO Report Highlights Growing Global Cancer Burden and Disparities in Access to Care
medlr.in
To view or add a comment, sign in